Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eiger Biopharmaceuticals (EIGRQ)
OTHER OTC:EIGRQ
Holding EIGRQ?
Track your performance easily
EIGRQ Stock Chart & Stats
Day’s Range$8 - $8.5
52-Week Range― - ―
Previous Close$8.5
Volume49.00
Average Volume (3M)N/A
Market Cap
$12.59M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,480,797
10 Day Avg. Volume192
30 Day Avg. Volume952
Standard Deviation0.65
R-Squared0.05
Alpha0.00234
Financial Highlights & Ratios
Price to Book (P/B)-0.87
Price to Sales (P/S)0.80
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Eiger Biopharmaceuticals News
PremiumCompany Announcements
Eiger BioPharmaceuticals Files for Chapter 11, Warns Investors
PremiumCompany Announcements
Eiger BioPharmaceuticals Issues Chapter 11 Financial Update
PremiumCompany Announcements
Eiger BioPharmaceuticals Announces Bankruptcy and Liquidation Plan
PremiumCompany Announcements
Eiger BioPharmaceuticals Issues Cautionary Chapter 11 Reports
PremiumCompany Announcements
Eiger BioPharmaceuticals Cautions Investors Amid Bankruptcy
PremiumCompany Announcements
Eiger Biopharmaceuticals CFO Exits Amid Bankruptcy ReorganizationOwnership Overview
50.04% Insiders
0.02% Mutual Funds
0.60% Other Institutional Investors
48.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
EIGRQ FAQ
What was Eiger Biopharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Eiger Biopharmaceuticals’s market cap?
Currently, no data Available
When is Eiger Biopharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Eiger Biopharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Eiger Biopharmaceuticals overvalued?
According to Wall Street analysts Eiger Biopharmaceuticals’s price is currently Overvalued.
Does Eiger Biopharmaceuticals pay dividends?
Eiger Biopharmaceuticals does not currently pay dividends.
What is Eiger Biopharmaceuticals’s EPS estimate?
Eiger Biopharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eiger Biopharmaceuticals have?
Currently, no data Available
What happened to Eiger Biopharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eiger Biopharmaceuticals?
Among the largest hedge funds holding Eiger Biopharmaceuticals’s share is Carlson Capital LP. It holds Eiger Biopharmaceuticals’s shares valued at N/A.
---
Eiger Biopharmaceuticals Stock Smart Score
Company Description
Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.
---
EIGRQ Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---